BotableBook a call
FDA Warning Letter Explorer
Drugs · Oct 23, 2024

MedOffice Saglik Endustri Anonim Sirketi

6 extracted findings

FDA source excerpt, selected passage

Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).
02
Your firm failed to perform appropriate testing on your over-the-counter (OTC) drug products, including the identity and strength of each active ingredient, prior to release and distribution into the U.S. market. This includes your **(b)(4)** cream, **(b)(4)**, and **(b)(4)** drug products.
03
Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).
04
Your firm failed to adequately test incoming components, including your active pharmaceutical ingredients (APIs), for identity before using the components to manufacture your drug products. Additionally, your firm released API and other components for use in drug product manufacturing based on your supplier’s certificate of analysis (COA) without establishing the reliability of your incoming component suppliers’ test analyses at appropriate intervals.
05
Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).
06
Your firm failed to adequately validate the manufacturing processes and qualify the equipment used to manufacture your drug products. Additionally, you failed to demonstrate that your cleaning procedure is sufficient to appropriately clean each type of equipment, including filling equipment which is shared for multiple products, including non-drug products, in a reproducible and effective manner.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

21 CFR 211.165(a)21 CFR 211.84(d)(1)21 CFR 211.100(a)21 CFR 210

For background, see Process validation. Explore Botable’s work in Pharmaceuticals and Quality and regulatory operations.

Keep exploring

Find related letters →Browse your letters
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Book a call ↗Read the case studies

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

LinkedIn Email

You choose what to post or send. Sharing a link does not change access to this site.